Discovery of a parallel family of euglenatide analogs in Euglena gracilis
2025

Discovery of euglenatide analogs in Euglena gracilis

publication Evidence: moderate

Author Information

Author(s): Elbanna Ahmed H., Kou Xinhui, Prajapati Dilip V., Rakshit Surasree, Butcher Rebecca A.

Primary Institution: University of Florida

Hypothesis

Euglena gracilis produces a family of euglenatide analogs that differ from the original euglenatides in their chemical structure and biological activity.

Conclusion

Euglena gracilis produces euglenatide analogs that are less bioactive than the original euglenatides, indicating the importance of the triene structure for their activity.

Supporting Evidence

  • Euglena gracilis produces euglenatides A–C and their analogs A2–C2 in roughly equal amounts.
  • The euglenatide analogs have the same molecular weights as the original euglenatides but lack the triene chromophore.
  • Euglenatide B2 is about tenfold less potent than euglenatide B against A549 lung adenocarcinoma cells.

Takeaway

Scientists found new versions of a compound made by a tiny algae that are not as good at fighting cancer as the original ones.

Methodology

The study involved culturing Euglena gracilis in specific media and analyzing the extracts using molecular networking and LC-MS.

Limitations

The low abundance of some euglenatides and their analogs made purification for analysis challenging.

Digital Object Identifier (DOI)

10.1007/s13659-024-00490-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication